Everett Collection / Shutterstock.com
With its roots stretching back to oil company Shell, Crystallics underpins pharmaceutical research and development by investigating the crystalline structures of drugs and potential drug compounds. LSIPR reports.
Crystallics is a company based in Amsterdam that evaluates drug ingredients for the pharmaceutical industry. It is one of a handful of companies globally that underpins pharmaceutical research and development by investigating the crystalline structures of drugs and potential drug compounds to find their optimum form. Such research can be crucial to effective patent protection when a drug comes to market.
Marcel Hoffmann, chief scientific officer at Crystallics, recommends that his firm gets involved in IP early in the research chain. Even if a pharma company has existing IP, it may not be well covered, he says.
For example, if a company already has its own prior art, it may leave gaps and make it more difficult to secure patent protection.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Crystallics; patents; pharmaceuticals